Ke Wang

Dr. Ke Wang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in Chest
Verified
Journal Article
Closed access
HCHong Chen
Hong Chen
ZDZheng-Xu Deng
Zheng-Xu Deng
JSJian Sun
Jian Sun
QHQiang Huang
Qiang Huang
LHLan Huang
Lan Huang
KWKe Wang
Ke Wang

24 August 2023 in Composites Science and Technology
Verified
Journal Article
Closed access
QZQi Zhang
Qi Zhang
KWKe Wang
Ke Wang
XCXianchun Chen
Xianchun Chen
XTXiaohong Tang
Xiaohong Tang
QZQian Zhao
Qian Zhao
QFQiang Fu
Qiang Fu

1 October 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ZQZhi-Xin Qiu
Zhi-Xin Qiu
PZPing Zhou
Ping Zhou
KWKe Wang
Ke Wang
Objectives: Lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). No clinical trials have been performed, and no course of treatment for LELC has been established because of it’s rarity. This study presents a patient with primary pulmonary LELC, who was treated with nivolumab, and responded favorably. Materials and methods: A patient with primary pulmonary LELC was treated using nivolumab. Result: The patient responded well to immunotherapy with nivolumab. After five cycles of the nivolumab, the size of the tumor and the lesions of the liver became smaller. A blood test showed that CYFRA21-1 and NSE had dramatically decreased from before, especially the CYFRA21-1. Conclusion: EBV-positive pulmonary LELC with high expression of PD-L1 may derive a benefit from PD-1/PD-L1 blockade.

6 May 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
YCYao Cheng
Yao Cheng
KWKe Wang
Ke Wang
JGJunhua Gong
Junhua Gong
ZLZuojin Liu
Zuojin Liu
JGJianping Gong
Jianping Gong
XWXiaomei Wang
Xiaomei Wang
Background Management of the open abdomen is a considerable burden for patients and healthcare professionals. Various temporary abdominal closure techniques have been suggested for managing the open abdomen. In recent years, negative pressure wound therapy (NPWT) has been used in some centres for the treatment of non‐trauma patients with an open abdomen; however, its effectiveness is uncertain. Objectives To assess the effects of negative pressure wound therapy (NPWT) on primary fascial closure for managing the open abdomen in non‐trauma patients in any care setting. Search methods In October 2021 we searched the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL EBSCO Plus. To identify additional studies, we also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta‐analyses, and health technology reports. There were no restrictions with respect to language, date of publication, or study setting. Selection criteria We included all randomised controlled trials (RCTs) that compared NPWT with any other type of temporary abdominal closure (e.g. Bogota bag, Wittmann patch) in non‐trauma patients with open abdomen in any care setting. We also included RCTs that compared different types of NPWT systems for managing the open abdomen in non‐trauma patients. Data collection and analysis Two review authors independently performed the study selection process, risk of bias assessment, data extraction, and GRADE assessment of the certainty of evidence. Main results We included two studies, involving 74 adults with open abdomen associated with various conditions, predominantly severe peritonitis (N = 55). The mean age of the participants was 52.8 years; the mean proportion of women was 39.2%. Both RCTs were carried out in single centres and were at high risk of bias. Negative pressure wound therapy versus Bogota bag We included one study (40 participants) comparing NPWT with Bogota bag. We are uncertain whether NPWT reduces time to primary fascial closure of the abdomen (NPWT: 16.9 days versus Bogota bag: 20.5 days (mean difference (MD) ‐3.60 days, 95% confidence interval (CI) ‐8.16 to 0.96); very low‐certainty evidence) or adverse events (fistulae formation, NPWT: 10% versus Bogota: 5% (risk ratio (RR) 2.00, 95% CI 0.20 to 20.33); very low‐certainty evidence) compared with the Bogota bag. We are also uncertain whether NPWT reduces all‐cause mortality (NPWT: 25% versus Bogota bag: 35% (RR 0.71, 95% CI 0.27 to 1.88); very low‐certainty evidence) or length of hospital stay compared with the Bogota bag (NPWT mean: 28.5 days versus Bogota bag mean: 27.4 days (MD 1.10 days, 95% CI ‐13.39 to 15.59); very low‐certainty evidence). The study did not report the proportion of participants with successful primary fascial closure of the abdomen, participant health‐related quality of life, reoperation rate, wound infection, or pain. Negative pressure wound therapy versus any other type of temporary abdominal closure There were no randomised controlled trials comparing NPWT with any other type of temporary abdominal closure. Comparison of different negative pressure wound therapy devices We included one study (34 participants) comparing different types of NPWT systems (Suprasorb CNP system versus ABThera system). We are uncertain whether the Suprasorb CNP system increases the proportion of participants with successful primary fascial closure of the abdomen compared with the ABThera system (Suprasorb CNP system: 88.2% versus ABThera system: 70.6% (RR 0.80, 95% CI 0.56 to 1.14); very low‐certainty evidence). We are also uncertain whether the Suprasorb CNP system reduces adverse events (fistulae formation, Suprasorb CNP system: 0% versus ABThera system: 23.5% (RR 0.11, 95% CI 0.01 to 1.92); very low‐certainty evidence), all‐cause mortality (Suprasorb CNP system: 5.9% versus ABThera system: 17.6% (RR 0.33, 95% CI 0.04 to 2.89); very low‐certainty evidence), or reoperation rate compared with the ABThera system (Suprasorb CNP system: 100% versus ABThera system: 100% (RR 1.00, 95% CI 0.90 to 1.12); very low‐certainty evidence). The study did not report the time to primary fascial closure of the abdomen, participant health‐related quality of life, length of hospital stay, wound infection, or pain. Authors' conclusions Based on the available trial data, we are uncertain whether NPWT has any benefit in primary fascial closure of the abdomen, adverse events (fistulae formation), all‐cause mortality, or length of hospital stay compared with the Bogota bag. We are also uncertain whether the Suprasorb CNP system has any benefit in primary fascial closure of the abdomen, adverse events, all‐cause mortality, or reoperation rate compared with the ABThera system. Further research evaluating these outcomes as well as participant health‐related quality of life, wound infection, and pain outcomes is required. We will update this review when data from the large studies that are currently ongoing are available.

21 December 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HWHong‐Xia Wu
Hong‐Xia Wu
KZKai‐Quan Zhuo
Kai‐Quan Zhuo
KWKe Wang
Ke Wang
Anti‐human epidermal growth factor receptor 2 (HER2) therapy is an effective treatment for HER2‐positive gastric and breast malignancies. However, the efficacy of HER2‐targeted therapy in non‐small cell lung cancer (NSCLC) patients with HER2 alterations remains controversial. We searched studies on HER2‐targeted therapy in NSCLC patients that reported objective response rate (ORR), disease control rate (DCR) and progressionfree survival (PFS) published from database inception to 30 May 2021. A total of 32 trials involving 958 patients were included. The ORRs of HER2‐TKIs targeted therapy, humanised monoclonal antibody, trastuzumab‐based treatment and antibody‐drug conjugate (ADC) (T‐DM1) were 22% (95% CI 11–31), 23% (95% CI 20–65), 26% (95% CI 14–39) and 16% (95% CI _6–37), while that of ADC (DS‐8201) was 60% (95% CI 35–85). The DCRs of these groups were 59% (95% CI 49–69), 39% (95% CI _9–88), 63% (95% CI 37–89), 31% (95% CI 4–58) and 87% (95% CI 62–112), respectively. In the subgroup analysis, numerically higher ORRs and DCRs were observed in the poziotinib (38%; 75%) and pyrotinib (35%; 83%) groups. The median PFSs of these groups were 5.51 months, 3.09 months, 4.61 months, 2.65 months and 12.04 months, respectively. HER2‐targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS‐8201), pyrotinib and poziotinib demonstrated promising anti‐tumour activity in HER2‐positive NSCLC.

15 July 2022 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
YLYan Lin
Yan Lin
JLJia-Yi Li
Jia-Yi Li
KWKe Wang
Ke Wang
ZFZhengfeng Fang
Zhengfeng Fang
LCLianqiang Che
Lianqiang Che
DWDe Wu
De Wu
Sperm and seminal plasma are rich in leucine, and leucine can promote the protein synthesis. This property makes it an interesting amino acid to increase sperm quality of human and livestock spermatogenesis. The goal of this study was to explore the effects of dietary leucine supplementation on testicular development and semen quality in boars from weaning to 10 months of age. 30 pure-bred, weaned Duroc boars (8.0 ± 1.0 kg) were randomly divided into two groups: control group (CON; fed the basal diet) and leucine group (LEU; fed the basal diet supplemented with 1.2% leucine); then, their body weight and testicular volume were recorded every 4 weeks. Testes were collected for histological and genes expression analysis from 150-day-old boars. Semen was collected and analyzed. Amino acids contents of blood plasma, seminal plasma, sperm, and testes were determined. Dietary supplementation with leucine increased the testicular volume and weight of boars, compared with CON. Sperm viability, sperm count per ejaculation, and average curve speed of sperm in leucine-supplemented boars were increased. Furthermore, leucine supplementation increased the blood plasma and seminal plasma leucine concentrations, and enhanced the gene expressions of branch chain amino acid transaminase, protein kinase B, mammalian target of rapamycin (mTOR), and cyclinb1 in the testes. Interestingly, the expressions of the p-mTOR and mTOR proteins in the testes were also upregulated. Thus, dietary leucine supplementation increased leucine absorption and utilization in the testes, promoted testicular development, and improved semen quality of boars, partly through the mTOR signaling pathway.